Literature DB >> 20921116

Regional brain volume in depression and anxiety disorders.

Marie-José van Tol1, Nic J A van der Wee, Odile A van den Heuvel, Marjan M A Nielen, Liliana R Demenescu, André Aleman, Remco Renken, Mark A van Buchem, Frans G Zitman, Dick J Veltman.   

Abstract

CONTEXT: Major depressive disorder (MDD), panic disorder, and social anxiety disorder are among the most prevalent and frequently co-occurring psychiatric disorders in adults and may have, at least in part, a common etiology.
OBJECTIVE: To identify the unique and shared neuroanatomical profile of depression and anxiety, controlling for illness severity, medication use, sex, age of onset, and recurrence.
DESIGN: Cross-sectional study.
SETTING: Netherlands Study of Depression and Anxiety. PARTICIPANTS: Outpatients with MDD (n = 68), comorbid MDD and anxiety (n = 88), panic disorder, and/or social anxiety disorder without comorbid MDD (n = 68) and healthy controls (n = 65). MAIN OUTCOME MEASURES: Volumetric magnetic resonance imaging was conducted for voxel-based morphometry analyses. We tested voxelwise for the effects of diagnosis, age at onset, and recurrence on gray matter density. Post hoc, we studied the effects of use of medication, illness severity, and sex.
RESULTS: We demonstrated lower gray matter volumes of the rostral anterior cingulate gyrus extending into the dorsal anterior cingulate gyrus in MDD, comorbid MDD and anxiety, and anxiety disorders without comorbid MDD, independent of illness severity, sex, and medication use. Furthermore, we demonstrated reduced right lateral inferior frontal volumes in MDD and reduced left middle/superior temporal volume in anxiety disorders without comorbid MDD. Also, patients with onset of depression before 18 years of age showed lower volumes of the subgenual prefrontal cortex.
CONCLUSIONS: Our findings indicate that reduced volume of the rostral-dorsal anterior cingulate gyrus is a generic effect in depression and anxiety disorders, independent of illness severity, medication use, and sex. This generic effect supports the notion of a shared etiology and may reflect a common symptom dimension related to altered emotion processing. Specific involvement of the inferior frontal cortex in MDD and lateral temporal cortex in anxiety disorders without comorbid MDD, on the other hand, may reflect disorder-specific symptom clusters. Early onset of depression is associated with a distinct neuroanatomical profile that may represent a vulnerability marker of depressive disorder.

Entities:  

Mesh:

Year:  2010        PMID: 20921116     DOI: 10.1001/archgenpsychiatry.2010.121

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  121 in total

1.  Associations of current and remitted major depressive disorder with brain atrophy: the AGES-Reykjavik Study.

Authors:  M I Geerlings; S Sigurdsson; G Eiriksdottir; M E Garcia; T B Harris; T Sigurdsson; V Gudnason; L J Launer
Journal:  Psychol Med       Date:  2012-05-30       Impact factor: 7.723

2.  Persistent β2*-nicotinic acetylcholinergic receptor dysfunction in major depressive disorder.

Authors:  Aybala Saricicek; Irina Esterlis; Kathleen H Maloney; Yann S Mineur; Barbara M Ruf; Anjana Muralidharan; Jason I Chen; Kelly P Cosgrove; Rebecca Kerestes; Subroto Ghose; Carol A Tamminga; Brian Pittman; Frederic Bois; Gilles Tamagnan; John Seibyl; Marina R Picciotto; Julie K Staley; Zubin Bhagwagar
Journal:  Am J Psychiatry       Date:  2012-08       Impact factor: 18.112

3.  A comparison of structural connectivity in anxious depression versus non-anxious depression.

Authors:  Lauren Delaparte; Fang-Cheng Yeh; Phil Adams; Ashley Malchow; Madhukar H Trivedi; Maria A Oquendo; Thilo Deckersbach; Todd Ogden; Diego A Pizzagalli; Maurizio Fava; Crystal Cooper; Melvin McInnis; Benji T Kurian; Myrna M Weissman; Patrick J McGrath; Daniel N Klein; Ramin V Parsey; Christine DeLorenzo
Journal:  J Psychiatr Res       Date:  2017-01-24       Impact factor: 4.791

4.  Multimodal voxel-based meta-analysis of white matter abnormalities in obsessive-compulsive disorder.

Authors:  Joaquim Radua; Mar Grau; Odile A van den Heuvel; Michel Thiebaut de Schotten; Dan J Stein; Erick J Canales-Rodríguez; Marco Catani; David Mataix-Cols
Journal:  Neuropsychopharmacology       Date:  2014-01-10       Impact factor: 7.853

Review 5.  Emotional and behavioral symptoms in neurodegenerative disease: a model for studying the neural bases of psychopathology.

Authors:  Robert W Levenson; Virginia E Sturm; Claudia M Haase
Journal:  Annu Rev Clin Psychol       Date:  2014-01-15       Impact factor: 18.561

6.  Limbic and prefrontal neural volume modulate social anxiety in children at temperamental risk.

Authors:  Eran S Auday; Koraly E Pérez-Edgar
Journal:  Depress Anxiety       Date:  2019-08       Impact factor: 6.505

7.  Cortical Thickness and Anxiety Symptoms Among Cognitively Normal Elderly Persons: The Mayo Clinic Study of Aging.

Authors:  Anna Pink; Scott A Przybelski; Janina Krell-Roesch; Gorazd B Stokin; Rosebud O Roberts; Michelle M Mielke; Kathleen A Spangehl; David S Knopman; Clifford R Jack; Ronald C Petersen; Yonas E Geda
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2016-08-31       Impact factor: 2.198

Review 8.  Neurobiology of anxious depression: a review.

Authors:  Dawn F Ionescu; Mark J Niciu; Daniel C Mathews; Erica M Richards; Carlos A Zarate
Journal:  Depress Anxiety       Date:  2013-03-11       Impact factor: 6.505

9.  Gray and white matter volume abnormalities in generalized anxiety disorder by categorical and dimensional characterization.

Authors:  Kevin Hilbert; Daniel S Pine; Markus Muehlhan; Ulrike Lueken; Susann Steudte-Schmiedgen; Katja Beesdo-Baum
Journal:  Psychiatry Res       Date:  2015-10-13       Impact factor: 3.222

10.  Cortical abnormalities and association with symptom dimensions across the depressive spectrum.

Authors:  Marc S Lener; Prantik Kundu; Edmund Wong; Kaitlin E Dewilde; Cheuk Y Tang; Priti Balchandani; James W Murrough
Journal:  J Affect Disord       Date:  2015-10-30       Impact factor: 4.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.